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Nuclear Translocation of the p75 Neurotrophin Receptor
Cytoplasmic Domain in Response to Neurotrophin Binding
Jose´ M. Frade
Instituto Cajal, Consejo Superior de Investigaciones Cientı´ficas, E-28002 Madrid, Spain
The intracellular domain of the p75 neurotrophin receptor (p75ICD) can be released by-secretase in response to the previous activation
of -secretase by phorbol esters. However, ligand-dependent release of p75ICD has yet to be described. We show here that nerve growth
factor can induce the release of p75ICD and facilitate its translocation to the nucleus in a -secretase-dependent manner. This effect was
observed in RN22 schwannoma cells cultured under serum-free conditions, as well as in Schwann cells, and it was mimicked by other
neurotrophins, such as brain-derivedneurotrophic factor or neurotrophin-3. Unlike other known examples of regulated intramembrane
proteolysis, ligand-dependent release of p75ICD did not need the previous activation of -secretase. These results suggest that nuclear
translocation of p75ICD may represent a novel neurotrophin-mediated signaling pathway.
Key words: -secretase; -secretase; p75NTR; neurotrophin; nuclear translocation; regulated intramembrane proteolysis
Introduction
The neurotrophin family is composed of nerve growth factor
(NGF), brain-derived neurotrophic factor (BDNF), neuro-
trophin-3 (NT3) and neurotrophin-4/5. These molecules act as
ligands for the Trk neurotrophic receptor tyrosine kinases, as well
as for the common p75 neurotrophic receptor (p75NTR), a mem-
ber of the tumor necrosis factor (TNF) receptor family (Lo´pez-
Sa´nchez and Frade, 2002). In recent years, a number of signaling
pathways have been described thatmediate the response of ligand
binding to p75NTR (Lo´pez-Sa´nchez and Frade, 2002). More re-
cently, the activation of -secretase by phorbol esters was shown
to provoke the release of the intracellular domain of p75NTR
(p75ICD) in a number of cell lines, including RN22 schwannoma
cells (RN22-SCs) (Jung et al., 2003; Kanning et al., 2003). How-
ever, evidence for ligand-mediated intramembrane cleavage of
p75NTR has yet to be presented. In this article, we show that
endogenously expressed p75ICD can be released and translocated
to the nucleus in response to both NGF and other neurotrophins.
Moreover, it seems that the release of p75ICD is independent of
metalloproteinase-dependent shedding of the p75NTR ectodomain.
Materials andMethods
Materials. All of the chemical reagents were purchased from Sigma (St.
Louis, MO) unless otherwise stated. The rabbit polyclonal antisera
(9992) against p75 ICD and against the extracellular domain of p75NTR
(p75ECD) (9651; diluted 1:800 for immunocytochemistry; diluted 1:2000
for Western blots) and the affinity-purified antiserum against the C ter-
minus of SC-1 (used at 4 g/ml) were kindly provided by Moses Chao
(New York University, New York, NY). The anti-human p75 ICD poly-
clonal antiserum (diluted 1:500; Promega, Madison, WI) also revealed
nuclear staining in response to NGF (data not shown). The anti-
neurotrophin receptor homolog 2 (NRH2) antiserum (kindly provided
by Phil Barker, McGill University, Montreal, Que´bec, Canada) was di-
luted 1:800 (immunocytochemistry), diluted 1:5000 (immunodeple-
tion), or diluted 1:10,000 (Western blotting). The amyloid precursor
protein (APP)-specific monoclonal antibody 22C11 (Chemicon, Hamp-
shire, UK) was used at 5 g/ml. The -secretase inhibitor N-[N-(3,5-
difluorophenacetyl)-L-alanyl]-(S)-phenylglycine t-butyl ester (DAPT)
was used at 1 M, the metalloproteinase inhibitor TNF- protease
inhibitor-2 (TAPI-2) was used at 20 M, and the metalloproteinase in-
hibitor GM 6001 was used at 10 M (all purchased from Calbiochem, La
Jolla, CA). PMA was used at 100 ng/ml. Human recombinant NGF-,
BDNF, and NT3 were stored at 10 ng/l in PBS/0.5% bovine serum
albumin andwere used at 100 ng/ml unless otherwise stated. TrkB recep-
tor bodies (human TrkB/Fc chimera; R & D Systems, Abingdon, UK)
were used at 1 g/ml.
Reverse transcription-PCR. Amplification of cDNAs derived from
RN22-SCs, postnatal day 2 (P2) rat brain, or P2 rat cortex was performed
using standard procedures. The PCR primers used were as follows:
GAPDH (base pairs 502–521, 1101–1120; GenBank accession number
X02231), TrkB (base pairs 852–871, 1569–1588; GenBank accession
number M55291), TrkC (base pairs 266–285, 766–785; GenBank acces-
sion number L03813), NGF (base pairs 655–674, 973–992; GenBank
accession number M36589), BDNF (base pairs 564–583, 745–764; Gen-
Bank accession number M61178), and NT3 (base pairs 773–792, 1032–
1051; GenBank accession number NM_031073). TrkB/TrkC primers are
specific for both full-length and truncated forms.
Cell culture. RN22-SCs were maintained at 37°C in DMEM/10% FCS
(Invitrogen, Carlsbad, CA). For most experiments, RN22-SCs (10,000
cells/cm2) were initially cultured for 24 h in DMEM, whereas RN22-SCs
expressing human APP were cultured in DMEM/10% FCS. Schwann
cells from P2 mouse sciatic nerves were isolated as described by Chan et
al. (2000), and they were cultured (10,000 cells/cm2) for 15 h in DMEM
containing 2 M forskolin and bovine pituitary extract (BPE) diluted
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1:100. Cell death was determined using the In
Situ Cell Death Detection kit (Hoffman-La
Roche, Basel, Switzerland).
Immunocytochemistry. Cells were fixed with
4%paraformaldehyde (15min). Immunostain-
ing was performed following a protocol de-
scribed previously (Lo´pez-Sa´nchez et al., 2005).
Nuclei were counterstained with 1 g/ml pro-
pidium iodide or bisbenzimide.
Cell fractionation. All of the steps were per-
formed at 4°C. Cells were lysed in cytoplasmic
buffer (CB) (10mMHEPES, pH7.6, 60mMKCl,
1 mM EDTA, 0.075% Triton X-100, 1 mM DL-
dithiothreitol, and 1 protease inhibitor mix-
ture) and homogenized by passing them
through a 22 ga needle. The nuclei were spun
down at 325 g for 4 min, and the supernatant
was isolated (cytoplasmic fraction). The pellets
were washed with CB without detergent and
extracted in nuclear buffer (20 mM Tris-HCl,
pH 8.0, 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM
EDTA, 25% glycerol, and 1 protease inhibitor
mixture). NRH2 immunodepletion of nuclear
fractionswas performed in 50mMTris-HCl, pH
8.0, 168 mM NaCl, 0.6 mM MgCl2, 0.08 mM
EDTA, 10% glycerol, and 0.1% Triton X-100.
Removal of anti-NRH2 was performed with
protein G-agarose beads diluted 1:25 (Santa
Cruz Biotechnology, Santa Cruz, CA). Condi-
tioned media (7.5 ml) were concentrated using
Centriprep YM-30 (Millipore, Bedford, MA).
Total extracts were obtained by cell solubiliza-
tion in Laemli’s buffer.
Western blot. Total extracts (equivalent to
200,000 cells), nuclear and cytoplasmic extracts
(15 g of protein), or concentrated condi-
tioned media (equivalent to 330 l of original
culture media) were separated by SDS-PAGE on 11% acrylamide gels
under nonreducing conditions and transferred to Immun-Blot polyvi-
nylidene difluoride membranes (Bio-Rad, Hercules, CA). APP-
conditionedmedia (20l) were separated on 8% acrylamide gels. Mem-
branes were blocked in 5%nonfat driedmilk in PBSwith 0.1%Tween 20
(PBTw) for 1 h and incubated overnight at 4°C with the antisera in
blocking buffer. After being washed five times in PBTw, the membranes
were incubatedwith goat anti-rabbitHRP-conjugated antibody (Jackson
ImmunoResearch, West Grove, PA) diluted 1:50,000 in blocking buffer
(1 h) and washed as above. Protein bands were visualized using ECL
(Amersham Biosciences, Piscataway, NJ). The films were scanned, and
the relative optical density (ROD) of the bands was determined using the
Analytical Imaging Station (AIS) 4.0 (Imaging Research, St. Catharines,
Ontario, Canada). ROD values were normalized to the value of the pro-
tein bands from the control cultures.
Cell counting. Cells were examined by confocal microscopy to define
the subcellular localization of the immunostaining using a Leica (Nuss-
loch, Germany) TCF-4D confocal setup. Cell counting was performed
with a Nikon (Melville, NY) E80i microscope with phase contrast and
epifluorescence illumination. In other experiments, randomly selected
fields containing cells counterstained with bisbenzimide were digitalized
using a DXM1200F camera (Nikon), and the ROD for p75 ICD immuno-
staining was measured with AIS 4.0. The average ROD value of the cyto-
plasm defined the threshold that was used under all of the experimental
conditions to identify those cells with stronger nuclear labeling for
p75 ICD. This approach yielded results similar to those obtained by direct
visual counting (data not shown).On average, 500 cells were analyzed per
coverslip.
Statistical analysis. Quantitative data are shown as the mean  SEM
from n independent experiments. Statistical differences were analyzed
using the Student’s t test.
Results
NGF induces nuclear translocation of p75ICD in serum-free
cultured RN22-SCs
The SC line RN22 lacks the NGF-specific neurotrophic receptor
TrkA but contains high levels of p75NTR (Gentry et al., 2000). The
cellular distribution of p75ICD was determined in these cells by
immunocytochemistry, and laser-scanning confocal microscopy
confirmed that, in the presence of FCS, p75ICD did not accumu-
late in the nucleus (Fig. 1A) (Kanning et al., 2003). However, in
the absence of serum, the intensity of p75ICD labeling in the ma-
jority of nuclei was equivalent to or less than that in the cytoplasm
(Fig. 1B). In the presence ofNGF, a considerable accumulation of
p75ICD occurred in70% of nuclei, in contrast to control cells,
in which only 20% of the nuclei were strongly labeled for
p75ICD (Fig. 1C,E). The increase in the proportion of nuclei
strongly labeled for p75ICD was observed 10 min after the addi-
tion of NGF (Fig. 2A) and lasted for at least 24 h (data not
shown). The half-maximal effect of NGF was attained after 2–3
min. The proportion of nuclei strongly labeled for p75ICD in-
creased in a concentration-dependent manner, with 5–10
ng/ml NGF producing a half-maximal effect (Fig. 2B). Exposure
to DAPT prevented the increase in the proportion of nuclei that
accumulated high levels of p75ICD in response to NGF (Fig.
1D,E). Hence, the ligand-dependent release of p75ICD seems to
require -secretase activity. As expected, p75ECD immunolabel-
ing was absent from the nucleus, regardless of the presence or
absence of NGF or DAPT (Fig. 1F–H).
To confirm that the p75ICD does indeed accumulate in the
nucleus in response to NGF, nuclear and cytoplasmic extracts
Figure 1. NGF induces nuclear translocation of p75 ICD as revealed by immunocytochemistry. A–H, RN22-SCs cultured in the
presence (A) or absence (B–H) of FCS were treated for 1 h with vehicle (B, F ), NGF (C, G), DAPT, or both (D, H ) and then were
immunostained for p75 ICD (A–D) or p75 ECD ( F–H). B, Weak nuclear p75 ICD immunoreactivity was observed in most cells after
removal of FCS. However, exposure to NGF increased the proportion of nuclei containing strong nuclear p75 ICD staining (C, E ), an
effect that was inhibited by DAPT (D, E). C, Inset, Propidium iodide-labeled nucleus (red) with strong p75 ICD immunoreactivity
(green). F–H, p75 ECDwas never observed in the cell nucleus. I–L, Schwann cells cultured in the presence of FCS, forskolin, and BPE
( I–L) were treated for 2 h with vehicle ( J), NGF ( K), DAPT, or both ( L). The proportion of nuclei containing high levels of p75 ICD
increased in thepresence ofNGF (I,K ),whereas exposure toDAPTprevented this effect ofNGF (I, L). ***p0.001. Scale bar:A–D,
F–H, 14m; J–L, 10m. Cont, Control. Error bars represent SEM.
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were subjected to Western blotting with a p75ICD-specific anti-
serum. A 25 kDa band, characterized previously as p75ICD (Jung
et al., 2003; Kanning et al., 2003), was enriched in nuclear extracts
from RN22-SCs exposed to NGF for 2 h (n 2) (Fig. 3A). In the
presence of the -secretase inhibitor DAPT, the levels of this
protein diminished to those of control cells. Additional protein
bands of 28, 33, and 37 kDa were observed in these extracts, but
they remained at a similar intensity under all of the conditions
(Fig. 3A). These bands are likely to represent NRH2moieties that
cross-react with the anti-p75ICD antiserum because they were
also detected with the NRH2-specific antiserum (n  2) (Fig.
3A). Immunodepletion with this anti-NRH2 antiserum allowed
us to unambiguously identify the 25 kDa band corresponding to
p75ICD in the nuclear extracts from RN22-SCs (Fig. 3A). Densi-
tometric analysis demonstrated that this band was significantly
increased in the NGF-treated cultures, an increase that was pre-
vented by DAPT [control, 1; NGF, 9.63  1.88 ( p  0.01);
DAPT, 0.74 0.25; DAPT/NGF, 1.57 0.10; n 3].
In the cytoplasmic fractions, the p75ICD-specific antiserum
only detected the full-length p75NTR protein (Fig. 3A). Interest-
ingly, the intensity of the full-length protein was reduced in the
fraction obtained from the NGF-treated cells, in accordance with
the cleavage and nuclear translocation of p75ICD, and this de-
crease was blocked in the presence of DAPT [control, 1; NGF,
0.45 0.01 ( p 0.001); DAPT, 1.24 0.03; DAPT/NGF, 1.14
0.02; n  2]. No higher-mobility bands corresponding to the
p75NTR C-terminal domain were observed in the cytoplasmic
fraction, even in the presence of DAPT. Thus, the release of
p75ICD in response to NGF does not seem to require the previous
shedding of the ectodomain attributable to -secretase activity.
Alternatively, NGF might induce -secretase cleavage and the
release of the p75NTR extracellular domain, but immunoblotting
may not be sufficiently sensitive to detect the C-terminal frag-
ment in the presence of DAPT.
To discriminate between these two alternatives, total cell ex-
tracts were subjected to Western blotting with the p75ICD-
specific antiserum (Fig. 3B). This analysis confirmed that NGF
induces the accumulation of a faint 25 kDa band, and this effect is
blocked by DAPT. No high-mobility bands specific for the
p75NTR C-terminal domain were observed in extracts from cells
treated with NGF and DAPT, thus indicating that the release of
p75ICD does not seem to require two cleavage steps.
To study further whether the activation of -secretase is nec-
essary for the release of p75ICD provoked by NGF, culture media
conditioned by RN22-SCs were analyzed in Western blots using
the anti-p75ECD antiserum (Fig. 3C). A protein of 55 kDa was
identified in medium conditioned by NGF-treated cells but not
in medium from control cells. This protein was slightly larger
than the 50 kDa p75NTR ectodomain released by -secretase in
response to PMA in the presence of serum (n 2) (Weskamp et
al., 2004) (Fig. 3C) and could represent the complete p75NTR
ectodomain cleaved by -secretase. In agreement with this idea,
the intensity of this band in the medium conditioned by cells
treated with NGF was dramatically reduced by the presence of
DAPT [NGF, 1; DAPT/NGF, 0.08 0.06 ( p 0.05); n 3] (Fig.
3C). These data strongly suggest that the interaction of NGFwith
p75NTR results in -secretase cleavage of p75NTR without the
previous activation of-secretase.Moreover, it seems thatmatrix
metalloproteinases are not involved in the -secretase cleavage of
p75NTR. In the presence of TAPI-2, an inhibitor of matrix metal-
loproteinases that prevents PMA-dependent shedding of p75NTR
(Jung et al., 2003; Kanning et al., 2003;Weskamp et al., 2004), the
proportion of RN22-SC nuclei strongly labeled for p75ICD when
visualized by immunocytochemistry still increased in response to
NGF [control, 22.18 6.09%;NGF, 69.42 1.57% ( p 0.005);
TAPI-2, 24.49  3.09%; TAPI-2/NGF, 70.48  1.96% ( p 
0.001); n 3]. Likewise, the release of the p75NTR ectodomain in
response to NGF was not affected by the presence of TAPI-2
(NGF, 1; TAPI-2/NGF, 0.88 0.12; n 2; nonsignificant) (Fig.
3D). The activity of TAPI-2 under these conditions was con-
firmed by its ability to prevent APP shedding from RN22-SCs
expressing human APP [control, 1; TAPI-2, 0.18  0.03 ( p 
0.005); n  2] (Fig. 3D). The metalloproteinase inhibitor GM
6001 also failed to prevent the accumulation of p75ICD in the
nuclei of the RN22-SCs in response to NGF [control, 28.90 
8.80%; NGF, 73.21  6.71% ( p  0.005); GM 6001, 20.19 
5.16%; GM 6001/NGF, 85.24 0.69% ( p 0.001); n 4].
To determine whether p75ECD can also accumulate in the
cytoplasm in response to NGF, the cytoplasmic fractions of
RN22-SCs cultured with different combinations of NGF and
DAPT were analyzed by Western blot using the p75ECD-specific
antiserum. These cytoplasmic fractions did not contain the 55
kDa p75ECD but rather the full-length p75NTR, which was less
intense in the extracts obtained from NGF-treated cells than in
control cells [control, 1; NGF, 0.34  0.03 ( p  0.005); DAPT,
0.97 0.15; DAPT/NGF, 1.17 0.05; n 2] (Fig. 3C). A 28 kDa
protein band was also observed after all of the treatments, which
may be attributable to nonspecific binding, or it may correspond
to a degradation product of p75ECD. This bandmight account for
the strong staining for p75ECDobserved in the cytoplasmofNGF-
treated cells (Fig. 1G).
NGF induces nuclear translocation of p75ICD in
Schwann cells
We determined whether the nuclear accumulation of p75ICD in
response to NGF might occur in nontransformed cells. In
Schwann cells derived from P2 mice grown in DMEM supple-
mented with FCS, p75ICD did not accumulate in the nuclei (data
not shown).However, in the presence of forskolin andBPE,5%
of the nuclei contained p75ICD (Fig. 1 I). Moreover, in the pres-
ence of NGF, the proportion of p75ICD-immunoreactive nuclei
increased to25%, (Fig. 1 I,K). The effect of NGF on the nuclear
accumulation of p75ICD was inhibited by the addition of DAPT
(Fig. 1 I,L). Hence, the activation of p75NTR by NGF seems to
provoke regulated intramembrane proteolysis (RIP) and the nu-
clear translocation of p75ICD in primary cell cultures.
BDNF and NT3 also induce nuclear translocation of p75ICD
The possibility that other neurotrophins could induce nuclear
accumulation of p75ICD was also evaluated in RN22-SCs. Be-
Figure 2. Time course and dose–response of the NGF-induced nuclear translocation of
p75 ICD.A, Percentage of RN22-SC nucleiwith strong p75 ICD immunoreactivitywhen cultured in
the presence of NGF for the time periods indicated. B, Percentage of RN22-SC nuclei with strong
p75 ICD immunoreactivity in cells cultured for 24 h in the presence of the concentrations of NGF
indicated. Error bars represent SEM.
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cause these cells do not express eitherTrkB
orTrkC (Fig. 4F), any interference of these
BDNF- and NT3-specific tyrosine kinase
receptors with the signaling of p75NTR was
avoided. Both BDNF and NT3 increased
the proportion of cells showing strong nu-
clear p75ICD immunoreactivity in a man-
ner similar to NGF (Fig. 4A–D). These
data indicate that all of the neurotrophins
have a similar capacity to induce p75ICD
release and nuclear translocation.
We tested whether RN22-SCs cultured
in the absence of serum express NGF,
BDNF, orNT3. BDNF expression could be
detected by reverse transcription (RT)-
PCR in cDNAs derived from these cells
(Fig. 4E). This suggests that the presence
of endogenous BDNF in the culture me-
dium during the 24 h period before the
treatment with NGF could be responsible
for the 20% of nuclei strongly stained with
the anti-p75ICD antiserum under control
conditions (Fig. 1E). Indeed, the addition
of DAPT at the time of serum withdrawal
strongly reduced the background levels of
cells with strong nuclear p75ICD immuno-
reactivity [1.17 0.19% ( p 0.001); n
4]. Blockage of endogenous BDNF with
the addition of TrkB receptor bodies at the
time of serum withdrawal (1 g/ml) also
reduced the proportion of nuclei with high
levels of p75ICD immunoreactivity [8.69
0.21% ( p  0.005); n  4]. This indicates
that, during the period in which the RN22-
SCs are initially cultured in the absence of
serum,p75ICD accumulates in thenucleus in
response to ligand-mediated, -secretase-
dependent release of p75ICD. This effect
seems to be mediated at least partially by
BDNF.
Discussion
In this study, we present evidence that the activation of p75NTR
with NGF promoted the release of p75ICD via the activity of
-secretase. We show that the increased accumulation of p75ICD
in the nuclei of RN22-SCs or Schwann cells in the presence of
NGF was impaired by the -secretase inhibitor DAPT. Further-
more, the detection of a p75ICD-specific protein band in the nu-
clear and total cell extracts fromRN22-SCs treated withNGFwas
also inhibited by DAPT. Finally, Western blot analysis indicated
that the levels of full-length p75NTRwere reduced in the cytoplas-
mic and total cell extracts of RN22-SCs treated with NGF, sug-
gesting that p75ICD is released after neurotrophin binding. This
effect was also reversed by DAPT.
p75ICD accumulation in the nucleus was dependent on the
concentration ofNGF andwas completed in10min. This rapid
activation of -secretase has also been seen in other RIP para-
digms (Ray et al., 1999). Furthermore, the rapid response of
p75NTR is not unique because the association of TRAF6 (TNF
receptor-associated factor 6) with p75NTR occurs 1 min after
NGF treatment and also reaches amaximum after 10min (Khur-
sigara et al., 1999). In contrast, internalization of p75NTR in re-
sponse to neurotrophins is much slower, taking45 min (Bron-
fman et al., 2003). This suggests that the release of p75NTR does
not need a previous internalization step and that it can take place
directly at the cell surface. It is unclear why neurotrophin-
dependent RIP of p75NTR was only observed when RN22-SCs
were cultured in serum-freemedium. Schwann cells grown in the
presence of serum, forskolin, andBPE showed a similar, although
less pronounced, effect in response to NGF. It is possible that
protein kinase A (PKA), an indirect target of forskolin, might
sensitize Schwann cells to undergo RIP in response to NGF. In-
deed, PKA has been shown to be necessary for TNF receptor-1
shedding (Douvdevani et al., 1996).
The capacity of p75NTR to translocate its intracellular domain
to the nucleus in response to ligand activation resembles the
pathway used by Notch or ErbB-4 to transduce intracellular sig-
nals (Ebinu and Yankner, 2002). Unlike these receptors, p75NTR
seems to undergo ligand-dependent RIP in the absence of
-secretase-dependent ectodomain shedding. This conclusion
was based first on the failure to detect the C-terminal p75NTR
fragment derived from ectodomain shedding of the receptor in
the cytoplasmic and total cell extracts from NGF-treated RN22-
SCs cultured in the presence of DAPT. Moreover, the p75ECD
released in response to NGF as a 55 kDa fragment is larger than
the p75NTR ectodomain released by -secretase (Weskamp et al.,
Figure 3. NGF induces p75 ECD shedding and nuclear accumulation of p75 ICD independent of metalloproteinases. Aa, Nuclear
extracts (15g) from RN22-SCs treated for 2 h with vehicle (Control), NGF, DAPT, or both (DAPT/NGF). The p75 ICD was observed
as a 25 kDa band in the NGF-treated cells (asterisk), an effect that was prevented by DAPT. Ab, The 28, 33, and 37 kDa bands
observed in these extracts were also recognized by the NRH2-specific antiserum. Ad, The p75 ICD-specific band was clearly ob-
served in NRH2-immunodepleted nuclear extracts (15g) after a long exposure of themembranes, and its intensity augmented
in the presence of NGF. Af, The anti-p75 ICD antiserum recognized a p75 NTR-specific band in the cytoplasmic extracts (15g) of
RN22-SCs. The intensity of this band was reduced in the presence of NGF. B, Total cell extracts from RN22-SCs treated for 2 h as
above. The presence of NGF reduced the intensity of the p75 ICD-specific band (59 7% compared with control conditions; n
2; p 0.05) and induced the appearance of a faint band of 25 kDa (asterisk). Both of these effectswere prevented by adding 1M
DAPT. The C-terminal portion of p75 NTRwas not observed after-secretase inhibition by DAPT in extracts fromNGF-treated cells.
Ca, The anti-p75 ECD antiserum recognized a single 55 kDa band in the culture medium conditioned for 24 h by cells treated with
NGF. The intensity of this bandwas reduced in the presence of DAPT, and it was distinct from that released in response to PMA by
RN22-SCs cultured in the presence of FCS (Cb). Cc, The anti-p75 ECD antiserum recognized a p75 NTR-specific band in cytoplasmic
extracts (15g) from RN22-SCs, whichwas less intense in the presence of NGF. Da, The presence of TAPI-2 could not prevent the
release of p75 ECD from cells cultured in the presence of NGF as detected with the anti-p75 ECD antiserum. However, TAPI-2 did
prevent shedding of soluble APP in RN22-SCs expressing human APP (Db). See Results for quantification of the intensity of the
bands and statistical analysis. The amount of nuclear or cytoplasmic protein on the membranes per lane was similar in all of the
experiments as revealed by Ponceau S staining (Ac, Ae, Ag, B, Cd). Extracell., Extracellular.
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2004; this study), and blocking -secretase activity prevented the
NGF-dependent release of this 55 kDa ectodomain fragment.
Finally, the metalloproteinase inhibitors TAPI-2 and GM 6001
were both unable to reduce the proportion of nuclei with high
levels of p75ICD in RN22-SCs treated with NGF, and TAPI-2
could not prevent the release of the 55 kDa ectodomain fragment.
This novel behavior of p75NTR suggests that neurotrophin bind-
ing provokes conformational changes in its transmembrane do-
main necessary for -secretase cleavage.
In RN22-SCs grown with FCS, p75ICD was only observed in
cell extracts in the presence of proteasome inhibitors (Kanning et
al., 2003). Here, endogenously expressed p75ICD was detected in
FCS-depleted RN22-SCs without the need for proteasome inhib-
itors. One explanation for the stability of p75ICD in the absence of
FCS is that it may interact with proteins that stabilize it, as occurs
with Notch and APP (Kimberly et al., 2001). One such protein
that interacts with p75ICD is Schwann cell factor 1 (SC1), which is
located in the nucleus in the absence of FCS (Chittka and Chao,
1999). Indeed, we detected nuclear SC1 in RN22-SCs cultured in
the absence of serum (data not shown), consistent with the pos-
sibility that SC1 stabilizes p75ICD in the nucleus of these cells.
The analysis of the nuclear fraction by Western blotting with
the anti-p75ICD-specific antiserum identified the presence of 28,
33, and 37 kDa bands, whose intensity was not affected by the
experimental manipulations. These bands were probably the re-
sult of a cross-reaction with NRH2 because they were detected by
a well characterized anti-NRH2 antiserum (Paul et al., 2004)
Moreover, they were absent in the NRH2-immunodepleted nu-
clear fractions analyzed with the anti-p75ICD antiserum. For un-
known reasons, the NRH2-specific bands were not detected by
the p75ICD antiserum in total cell extracts, as described previ-
ously by Murray et al. (2004).
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